NPS leaps on upbeat US FDA Gattex review ahead of panel
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals' investigational short bowel syndrome (SBS) medicine Gattex (teduglutide) has had its share of ups and downs, but 12 October was a day investors viewed as optimistic, driving shares of the New Jersey firm up nearly 23% after the US FDA said it did not believe the drug should be restricted despite concerns about the risks of colon polyp and tumor growth, gastrointestinal obstruction and biliary and pancreatic disorders – outcomes that were observed in the experimental medication's development program.